A Two Arm Phase II Study of FOLFIRI in Combination With Standard or Escalating Dose of Cetuximab as First Line Treatment of K-Ras Wild Type Metastatic Colorectal Cancer: Everest 2.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 May 2017
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms Everest2
- 07 Jun 2017 Biomarkers information updated
- 02 Oct 2016 This trial was discontinued in Spain.
- 27 Aug 2016 This trial was discontinued in Austria.